NRG Oncology is pleased to announce the start of our new initiative to provide patient-friendly summaries of recently published results of NRG Oncology studies. The first two study results summaries to be released and published on the group’s website are for NCORP studies NRG-CC001, A Randomized, Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases, and NRG-CC004, Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer. These are now available on the NRG Oncology patient study webpages (https://www.nrgoncology.org/CC001 and https://www.nrgoncology.org/CC004).
The summaries mark the culmination of NRG Oncology’s ongoing efforts to disseminate research results to the patients who participated in the group’s studies. Moving forward, NRG Oncology will release a patient-friendly summary of research results documents for all NRG Oncology studies after the study’s primary endpoint is reported. The documents will include the study backgrounds and rationales, major findings, recommendations for study participants and others with similar medical conditions, and a list of study-generated publications.
The NRG Oncology Operations Office will develop the summaries with input from the study team and the appropriate NRG Oncology committee chair and patient advocate committee members. The NRG Oncology Weekly Broadcast will announce the availability of the summaries as they are published, so that sites can share results with study participants. Please stay tuned for announcements of additional summaries of research as they become available!